World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
83
Citations
26824
World Ranking
1434
National Ranking
729

Medicine

D-Index
83
Citations
26824
World Ranking
15549
National Ranking
7836

Richard T. Davey publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Richard T. Davey sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 207 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Richard T. Davey D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Richard T. Davey sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 83 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Richard T. Davey is affiliated with the National Institute of Allergy and Infectious Diseases in the United States. Their research primarily focuses on the field of Medicine, with a significant number of publications in Infectious Diseases. Subfields of study include Epidemiology, Neurology, Immunology, and Emergency Medical Services.

The scientist's research topics involve a range of areas related to viral infections and immune response. These topics include:

  • COVID-19 Clinical Research Studies
  • Viral Infections and Outbreaks Research
  • SARS-CoV-2 and COVID-19 Research
  • Hepatitis B Virus Studies
  • Long-Term Effects of COVID-19
  • Disaster Response and Management
  • Viral Infections and Vectors

Richard T. Davey has contributed to several recent publications, mostly centered around COVID-19 and related viral infections. Notable papers include:

  • "Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19," 2020, published in New England Journal of Medicine
  • "Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019," 2020, published in The Journal of Infectious Diseases
  • "Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients," 2020, published in bioRxiv (Cold Spring Harbor Laboratory)
  • "Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic," 2020, published in The Journal of Infectious Diseases
  • "Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial," 2021, published in Clinical Infectious Diseases

Their frequent co-authors have included:

  • Daniel S. Chertow
  • Jeffrey R. Strich
  • Aneesh K. Mehta
  • Cameron R. Wolfe
  • Nadine Rouphael

Research outputs have been published across several venues, with a concentration in journals focused on infectious diseases and clinical medicine. Frequent publication venues include:

  • The Journal of Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Annals of Internal Medicine
  • New England Journal of Medicine
  • Clinical Infectious Diseases

Best Publications

  • Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

    Andre C Kalil;Thomas F Patterson;Aneesh K Mehta;Kay M Tomashek

  • A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

    Mulangu S;Dodd Le;Davey Rt;Tshiani Mbaya O

  • HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

    Richard T. Davey;Niranjan Bhat;Christian Yoder;Tae Wook Chun

  • Persisting Illness and Fatigue in Adults with Evidence of Epstein-Barr Virus Infection

    S E Straus;G Tosato;G Armstrong;T Lawley

  • CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.

    H Masur;F P Ognibene;R Yarchoan;J H Shelhamer

  • Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis

    Sarah Palmer;Mary Kearney;Frank Maldarelli;Elias K. Halvas

  • A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

    Davey Rt;Dodd L;Proschan Ma

  • Re-emergence of HIV after stopping therapy

    T W Chun;R T Davey;D Engel;H C Lane

  • Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.

    Joseph A. Kovacs;Susan Vogel;Jeffrey M. Albert;Judith Falloon

  • Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

    Tae Wook Chun;Richard T. Davey;Mario Ostrowski;J. Shawn Justement

  • Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

    Chun Tw;Engel D;Mizell Sb;Hallahan Cw

  • Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

    J A Kovacs;M Baseler;R J Dewar;S Vogel

  • A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

    Jason A. Regules;John H. Beigel;Kristopher M. Paolino;Jocelyn Voell

  • Clinical Management of Ebola Virus Disease in the United States and Europe.

    Timothy M. Uyeki;Aneesh K. Mehta;Richard T. Davey;Allison M. Liddell

  • A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS

    A G Palestine;M A Polis;M D De Smet;B F Baird

  • ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

    Frank Maldarelli;Sarah Palmer;Martin S King;Ann Wiegand

  • Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

    Matthew J. Memoli;Pamela A. Shaw;Alison Han;Lindsay Czajkowski

  • Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.

    Peter D Burbelo;Francis X Riedo;Chihiro Morishima;Stephen Rawlings

  • Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

    Robert E. Walker;Christine M. Bechtel;Ven Natarajan;Michael Baseler

  • High-level HIV-1 viremia suppresses viral antigen-specific CD4+ T cell proliferation

    McNeil Ac;Shupert Wl;Iyasere Ca;Hallahan Cw

  • Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.

    H. Clifford Lane;Victoria Davey;Joseph A. Kovacs;Judith Feinberg

  • Evidence for increased T cell turnover and decreased thymic output in HIV infection.

    Daniel C. Douek;Michael R. Betts;Brenna J. Hill;Susan J. Little

Frequent Co-Authors

Julia A. Metcalf
Julia A. Metcalf National Institute of Allergy and Infectious Diseases
H. Clifford Lane
H. Clifford Lane National Institute of Allergy and Infectious Diseases
Joseph A. Kovacs
Joseph A. Kovacs National Institutes of Health
Michael A. Polis
Michael A. Polis National Institute of Allergy and Infectious Diseases
Henry Masur
Henry Masur National Institutes of Health
Michael Baseler
Michael Baseler Leidos (United States)
Anthony S. Fauci
Anthony S. Fauci Georgetown University
Irini Sereti
Irini Sereti National Institutes of Health
Claire W. Hallahan
Claire W. Hallahan National Institute of Allergy and Infectious Diseases
Timothy M. Uyeki
Timothy M. Uyeki Centers for Disease Control and Prevention

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying immunology in the USA, exploring related healthcare degrees can open diverse career pathways. Many students transition into healthcare roles that complement immunology, such as nursing or specialized clinical practice.

Accelerated nursing programs offer fast-tracked options for individuals without a nursing background. If you’re looking to shift careers, consider accelerated BSN programs for non nurses that provide streamlined admission processes.

LPN programs also serve as an accessible entry point into healthcare. Those exploring practical nursing can find accredited LPN programs easy to get into, helping them build foundational skills needed in clinical and laboratory settings related to immunology.

For advanced practice, nurse practitioner programs with easy admission can help you quickly gain qualifications to engage with patient care and disease management, key areas tied to immunological health.

Lastly, if you have a passion for mental health alongside immunology, consider PMHNP programs online with best clinical placement. These programs ensure strong hands-on experience while accommodating flexible learning schedules.

Best Scientists Citing Richard T. Davey

Trending Scientists

Recently Published Articles